Literature DB >> 12813464

Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.

Patrizia Paterlini-Bréchot1, Kenichi Saigo, Yoshiki Murakami, Mounia Chami, Devrim Gozuacik, Claude Mugnier, David Lagorce, Christian Bréchot.   

Abstract

Integration of Hepatitis B Virus (HBV) DNA into liver cell DNA has been well established, but its implication in liver carcinogenesis is still being debated. In particular, insertion of the viral genome into cellular genes has been viewed as a rare event. By using HBV-Alu PCR, we have now isolated, from nine hepatocellular carcinomas, nine HBV-DNA integration sites showing that the viral genome mutates key regulatory cellular genes: neurotropic tyrosin receptor kinase 2 (NTRK2) gene, IL-1R-associated kinase 2 (IRAK2) gene, p42 mitogen-activated protein kinase 1 (p42MAPK1) gene, inositol 1,4,5-triphosphate receptor type 2 (IP3R2) gene, inositol 1,4,5-triphosphate receptor (IP3R) type 1 (IP3R1) gene, alpha 2,3 sialyltransferase (ST3GAL VI or SITA) gene, thyroid hormone uncoupling protein (TRUP) gene, EMX2-like gene, and human telomerase reverse transcriptase (hTERT) gene. This result brings to 15 the total number of genes targeted by HBV in a study of 22 human liver cancers. Overall, we found that both the inositol 1,4,5-triphosphate receptor gene and the telomerase gene were targeted by HBV in two different tumors. Thus, HBV frequently targets cellular genes involved in cell signalling and some of them may be preferential targets of the viral integration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813464     DOI: 10.1038/sj.onc.1206492

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  108 in total

Review 1.  The enigmatic X gene of hepatitis B virus.

Authors:  Michael J Bouchard; Robert J Schneider
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Emerging patterns of somatic mutations in cancer.

Authors:  Ian R Watson; Koichi Takahashi; P Andrew Futreal; Lynda Chin
Journal:  Nat Rev Genet       Date:  2013-09-11       Impact factor: 53.242

Review 3.  Update of research and management of hepatitis B.

Authors:  Takeshi Okanoue; Masahito Minami
Journal:  J Gastroenterol       Date:  2006-02       Impact factor: 7.527

Review 4.  Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.

Authors:  Lu Gan; Liwu Li
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 5.  Hepatitis B virus-induced oncogenesis.

Authors:  Joachim Lupberger; Eberhard Hildt
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 6.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

Review 7.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

Review 8.  Technical standards for hepatitis B virus X protein (HBx) research.

Authors:  Betty L Slagle; Ourania M Andrisani; Michael J Bouchard; Caroline G L Lee; J-H James Ou; Aleem Siddiqui
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

Review 9.  Viruses associated with human cancer.

Authors:  Margaret E McLaughlin-Drubin; Karl Munger
Journal:  Biochim Biophys Acta       Date:  2007-12-23

10.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.

Authors:  Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Ichiro Takasaki; Yoshiaki Tabuchi; Hua-chuan Zheng; Kazuhiro Nomoto; Hiroyuki Takahashi; Koichi Tsuneyama; Ichiro Kato; Daniel K Hsu; Fu-tong Liu; Koichi Hiraga; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.